Obesity, which refers to excessive body fat accumulation and adipose tissue hypertrophy [39], is a complex metabolic disease caused by a variety of non genetic and genetic factors [40], with the intensive study of the gut microbiota in obesity, the results all support that the gut microbiota can serve as a target for obesity treatment, and further exploration is needed. The study of the relationship between obesity and gut flora was the earliest study of the relationship between

human health and gut flora: germ free mice transplanted with normal gut flora were found to eat less and accumulate more fat after transplantation, which illustrated that the gut flora helped the animals to absorb calories from food more efficiently and become fat storing [41]. Recent studies have shown that the ratio of Firmicutes to Bacteroidetes in the gut is significantly higher in obese compared to lean subjects, while Bacteroidetes show the opposite trend, and the decreased number of genes in the gut flora is associated with severe metabolic abnormalities in obese subjects [42]; The microbiota differs significantly between obese and control subjects at different levels. The genera Prevotella, megamonas, Fusobacterium and blautia were significantly increased, while faecalibacterium, parabacteroides, Bifidobacterium and alistipes were significantly decreased in obese subjects; At the species level, nine species were significantly different between obese and control groups, among which Prevotella was significantly increased in the obese group [43]. A systematic review of randomized clinical trials of probiotics and synbiotics for weight loss in obese subjects suggested [44]: Probiotics and synbiotics from the Bifidobacterium genus Lactobacillus associated with other Lactobacillus species and/or species lactobacillus, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus curvatus strains could help overweight and obese people lose weight and fat mass. However, clinical trials are needed to make more accurate recommendations regarding strain, dose, and timing of intervention.

T2DM, a metabolic disease mainly characterized by hyperglycemia and insulin resistance, results from a combination of several factors including genetics, gender, lifestyle, diet, aging and epigenetics [45]. In recent years, an increasing number of studies have proved that intestinal flora is closely related to type 2 diabetes and may be another etiological factor leading to type 2 diabetes [46]. Two large-scale meta genomic analyses investigated the characteristics of the gut microbiota in T2DM patients and healthy individuals: bacteria enriched in Chinese T2DM patients were mainly conditional pathogens such as Escherichia coli, some clostridia, Bacteroides caccae and Eggerthella lenta, and decreased abundances of butyrate producing bacteria, including Eubacterium rectale, Clostridium difficile SS3/4, Faecalibacterium prausnitzii and intestinal Roseburia [24]. Increased abundances of Lactobacillus gasseri, Streptococcus mutans, some clostridia and lactobacilli and decreased abundances of butyrate producing bacteria, including Roseburia, Eubacterium IRI, Bacteroides enterica and some clostridia, have been reported in European women with T2DM [16]. A meta-analysis showed that probiotics improved HbA1c and fasting insulin in diabetes. The effect of synbiotic supplementation on patients with type 2 diabetes has received increasing attention. A fecal microbiota transplantation (FMT) for 24 weeks of T2DM Double-blind randomized controlled trial results: Repeated FMT increases the level and duration of microbiota engraftment in obese patients with T2DM. Combining a lifestyle intervention with FMT resulted in more favorable changes in the recipient’s microbiota and improved lipid levels and Liver stiffness. The effect of FMT on blood glucose in diabetic patients has not been reported, and further research is needed in the future.

HTN, defined as a condition in which arterial blood pressure is persistently high with a blood pressure value ≥ 140/90mmHg, often occurs in the middle-aged and elderly and obese individuals [47], is a cardiovascular syndrome in an evolving state caused by various factors (stress, physical inactivity, obesity, high sodium intake, unhealthy diet and possibly interacting genetic factors, etc.) [48] and is a risk factor associated with heart disease, stroke and chronic kidney disease with high morbidity and mortality, It is estimated that 16% - 37% of the global population has hypertensive disorders [49]. In recent years, increasing evidence has shown that the gut microbiota plays an important role in the development and pathogenesis of HTN and is an important player in the control of blood pressure [50]. Animal studies reported that the variation of fecal flora in essential hypertensive rats greatly exceeded that in normal rats, with a decrease in lipid and butyrate producing flora and a 5-fold increase in the Firmicutes to Bacteroidetes (F/b) ratio, an increase in microbial richness, diversity and even distribution degree and in DNA content per milliliter, and a marked decrease in the Firmicutes to Bacteroidetes ratio after 4 weeks of oral minocycline Administration [51]. In a study of 196 healthy individuals versus hypertensive patients, it was found that the number and diversity of gut microbial genes were significantly lower in the prehypertension group versus the healthy group, Prevotella and Klebsiella were significantly enriched in the prehypertension and HTN groups, some beneficial bacteria such as faecali, Rothia, oscillibacter were enriched in the healthy population and decreased significantly in the prehypertension and HTN groups [52]. In female hypertensive patients, an uncultured genus (erysipelotrichaceae-ucg003) of the family erysipelotrichaceae is present in higher relative abundance and ruminiclostridium 6 in lower relative abundance [53]; These results suggest that the overgrowth of some pathogenic bacteria and the lack of beneficial bacteria may jointly participate in the disease process of HTN. A 3-month multicenter, randomized, placebo-controlled, blinded clinical trial of oral FMT capsules or placebo capsules in 120 patients with grade 1 HTN is currently underway. All recruited patients will be randomized 1:1 to be taken on days 1, 7 and 14 and followed up on days 30, 60 and 90 in anticipation of good results. To date, there are no literature reports on the intervention of synbiotics in HTN.

Hyperlipidemia refers to the presence of excess fat or lipids in the blood [2], including increased levels of total cholesterol (TC), low-density lipoprotein (LDL) cholesterol and triglycerides (TG), and decreased high-density lipoprotein (HDL) cholesterol [54]. Is a major risk factor for cardiovascular disease (CVD) [55]. The etiology is the result of a combination of genes and environmental factors [56]. The gut microbiota has been reported to play a crucial role in regulating host lipid metabolism [2]. Animal experiments suggest a causative role of gut microbiota in the development of hyperlipidemia [57]. Microbiota associated metabolites such as BAS, LPS, TMAO, SCFA have been shown to modulate hyperlipidemia. Feces of hyperlipidemic children and adolescents had lower levels of SCFA producing bacteria such as those from lachnospiraceae and ruminococcaceae as well as those from akkermansia, Bacteroides, roseobacter and faecalibacterium [58]. A randomized controlled trial showed that feces of patients with metabolic syndrome (characterized by hyperlipidemia) have lower abundance of potential probiotics, such as Bifidobacterium, Lactobacillus, faecalibacterium prausnitzii and Roseburia, but higher abundance of LPS producing Escherichia coli and Enterobacter cloacae compared to feces of healthy individuals [59]. The data show that prebiotics, probiotics, and fecal microbiota transplantation have therapeutic effects on hyperlipidemia, indicating that intestinal flora may be a potential therapeutic target for hyperlipidemia [2].

HU, one of the major metabolic diseases caused by purine metabolism disorder, is clinically closely related to many diseases, such as diabetes, HTN, stroke, myocardial infarction [60]. In addition to causing gout attacks, and the prevalence rate has increased year by year in many countries, which has become a common disease that seriously threatens human health [61]. The intestine is the largest organ of the human body and has a huge potential for uric acid excretion [62], and studies have found that probiotic supplementation can reduce uric acid levels, suggesting that probiotics hold promise as a new direction for the treatment of gout and HU [63]. An analysis of gut flora characteristics in asymptomatic Hu (45 cases) versus healthy controls (45 cases) showed [64]: in asymptomatic HU, the abundance of bacteria such as alipipes, dialister, Roseburia, gemmiger and faecalibacterium was relatively high, while the abundance of bacteria such as Bifidobacterium, Klebsiella and Clostridium was relatively low, which was comparable to that of the asymptomatic Hu group α The diversity index was higher in cases than in controls, β Diversity indices also showed significant differences, and unclassified Enterobacteriaceae, Roseburia and faecalibacterium, had good diagnostic values for asymptomatic HU.

NAFLD, a metabolic disease characterized by the presence of hepatic steatosis, hepatic fat accumulation on imaging or histologic testing to exclude alcohol abuse or other causes of indeterminate liver damage [65], is a leading cause of chronic liver disease worldwide [66] and poses a serious threat to human health, which can evolve to nonalcoholic steatohepatitis (NASH), cirrhosis if NAFLD delays treatment, Even liver cancer [67], which can also present with a wide range of extrahepatic manifestations such as obesity, type 2 diabetes, metabolic syndrome, cardiovascular disease, chronic kidney disease, extrahepatic malignancies, cognitive impairment and polycystic ovary syndrome, is a multisystemic clinical disorder [68]. In recent years, studies on the gut flora, especially the regulation of key components and metabolites on the development and progression of NAFLD, have been conducted. The report of animal studies on the gut microbiota of NAFLD [69] [70] found that Firmicutes ↑ Actinobacteria ↑ Deferribacters ↓ Bacteroidetes ↓ Lactobacillus Murinus. Studies in patients with NAFLD have found [71] [72] ↑ Bacteroidaceae ↑ Prevotellaceae ↑ Proteobacteria ↑ Verrucomicrobia ↑ Actinobacteri ↓ Euryarchaeota ↓ Lachnospiraceae ↓ Ruminococcaceae ↓ Lactobacillaceae, suggesting that a higher proportion of gram negative bacteria (including Bacteroidetes) is associated with a decrease in short chain fatty acid (SCFA), producing Firmicutes; In children with NAFLD, gram negative bacterial species are overgrown, with increased proportions of gammaproteobacteria and epsilonproteobacteria compared with their obese and lean counterparts [73]. A meta-analysis of 15 randomized controlled trials of probiotics and synbiotics involving 782 patients with NAFLD showed that supplementation with probiotics and synbiotics was associated with significantly lower levels of TG, TC, HDL-C, LDL-C, and TNF-α. In general, probiotics/synbiotics are safe and well tolerated, and the long-term protection of NAFLD is sustainable, and further studies are warranted to more clearly elucidate the effectiveness of probiotics/synbiotics in NAFLD management, safety and sustainability.

AFLD is a fatty liver disease caused by a large amount of continuous alcohol intake, with a prevalence rate of 6% [74]. If only fat accumulates in the liver, it is called benign or simple fatty liver. Inflammatory reaction is called steatohepatitis. Without treatment or delay in treatment, it can form fibrosis and cirrhosis, and can also develop into hepatocellular carcinoma and liver failure, eventually leading to death. 20% of AFLD patients will develop into progressive liver disease [75]. It is the most common chronic liver disease in the western world and the main cause of liver transplantation [76]. More than 500,000 people worldwide die of alcoholic liver disease every year [77]. Animal studies have shown that three weeks of alcohol exposure will lead to “intestinal leakage”, thus increasing the number of bacteroides and verrucae, and reducing the growth of bacteria with anti-inflammatory activity in the cecum, such as chlamydia (genus, such as lactobacillus, lactococcus, Leuconostoc and Pediococcus) [78]. These changes were restored by probiotic Lactobacillus rhamnosus GG therapy. Cross study of human shows that drinking red wine will increase the number of bacteroides, enterococcus and bifidobacteria [79]. Research report on intestinal flora of AFLD [80]: ↑ Olsenella ↑ Eubacterium ↑ Activibrio ↑ Actinobacia ↑ Firms ↑ Coriobateriaceae ↑ Odoribacteriaceae ↑ Clostridiaceae ↑ Dora ↓ Proteobateria ↓ Bacteroides ↓ Acinetobacter ↓ Anaerotruncus ↓ Akkerman sia ↓ Blautia. In addition, fecal transplantation of alcohol fed wild rats in dwarf animals increased liver and intestinal inflammation, indicating that intestinal microbiota participated in AFLD [81]. Research report on intestinal microflora of AFLD [82] ↑ Candida spp. ↑ Candida albicans ↑ Candida dubliniensis ↑ Proteobasteria ↑ Fusobasteria ↑ Fusobasteriaceae ↑ Enterobasteriaceae ↑ Burkholderiae ↑ Escherichia Shigella ↓ Epicocum ↓ Unclassified fugi ↓ Galactomycete ↓ Debaryomyces ↓ Ruminococcaceae ↓ Faecaalibacterium ↓ ium ↓ Lachnospira ↓ Agathobacter ↓ Ruminococcus. Because the etiology and pathogenesis of AFLD are basically clear, and alcohol withdrawal is the fundamental method for the treatment of AFLD, there are few reports in the literature on clinical intestinal flora intervention in AFLD.

The World Health Organization defined the syndrome and changed its name to MetS [83]: Presence of insulin resistance or glucose > 6.1 mmol/L (110 mg/dl), 2 h glucose > 7.8 mmol (140 mg/dl) (required), along with any two or more of the following: 1) HDL cholesterol < 0.9 mmol/L (35 mg/dl) in men, <1.0 mmol/L (40 mg/dl) in women; 2) Triglycerides > 1.7 mmol/L (150 mg/dl); 3) Waist/hip ratio > 0.9 (men) or >0.85 (women) or BMI > 30 kg/m²; 4) Blood pressure > 140/90mmHg. In this literature review on obesity, HTN, hyperlipidemia and diabetes, it is shown that these metabolic diseases all have imbalance of intestinal flora, and MetS is bound to have stable intestinal flora, which is characterized by enrichment of potentially harmful bacteria and decline of beneficial bacteria [84].A meta-analysis of the application of probiotics, prebiotics, synbiotics, FMT and other microbial therapies in the treatment of MetS showed that microbial therapy can significantly improve FBG, TC, TG, HDL-C, LDL-C, WC, BMI, HOMA-IR and DBP, but no effect on SBP and HbA1c%.

PCOS is a common endocrine metabolic disease, which is the main cause of anovulatory infertility in women of childbearing age [85]. Its clinical manifestations include increased secretion of ovarian and/or adrenal androgens, cessation of follicular development [86], and a series of metabolic diseases related to PCOS, such as obesity, T2DM, MetS and gestational diabetes, nonalcoholic fatty liver [87]. The literature reported the changes of intestinal flora of PCOS [14]: Prevotella Bacteroides Streptococcus enrichment, Lactobacillus Ruminococcus Clostridium Akkermania Ruminococcaeae reduction; Animal experiment [88]: αdiversity in PNA animals ↑, β diversity: the PNA animal samples were further apart. Nocardiaceae and Clostridiaceae ↑, Akkermansia, Bacteroides, Lactobacillus, and Clostridium ↓; Results of 38 cases of PCOS and 26 cases of control group [89] Faecalibacterium, Bifidobacterium, and Blautia ↓ Parabolides, Bacteroides, Lactobacillus, Oscillibacter, Escherichia/Shigella, Clostridium ↑. These data suggest that PCOS has different degrees of gut microbiota imbalance, and various interventions to alter the stability of the gastrointestinal microbiota may be an effective treatment for PCOS. Numerous prebiotic, probiotic, and synbiotic treatment studies have been reported. So far, there is no report of FMT intervention on PCOS. This is an interesting thing and worth looking forward to.

WD, also known as hepatolenticular degeneration, is a disease of copper metabolism disorder and an autosomal recessive inheritance disease caused by ATP7B gene defect [90]. Recent studies have shown that environmental and dietary factors may change the gene expression of WD [91].

Fecal samples from 14 patients with WD and 16 healthy individuals were compared for 16S rRNA sequencing results [92]: the diversity and composition of the gut microbiome were significantly lower in the WD group than in healthy individuals. The WD group showed unique abundances of gemellaceae, pseudomonadaceae and lachnospiraceae at the family level, which were barely detected in healthy controls. Compared with healthy individuals, the WD group had significantly lower abundances of Actinobacteria, Firmicutes, and verrucomicrobia and higher abundances of Bacteroidetes, Proteobacteria, cyanobacteria, and fusobacteria. The Firmicutes to Bacteroidetes ratio was significantly lower in the WD group than in healthy controls. These results suggest that WD has a disturbance of the gut microbiota, is the pathogenesis of WD and a new possible therapeutic target? Due to the small number of WD cases, there is no literature report on the intervention of intestinal flora in clinical and animal experiments. This may provide a new direction for further research on WS.

OP is a chronic progressive metabolic osteopathy characterized by decreased bone density and destruction of bone tissue microstructure, which leads to increased bone fragility and easy fracture [93]. At present, there are four main aspects of clinical treatment: lifestyle change, nutritional supplements, drug intervention and surgical treatment [94]. The study on the composition of intestinal microbiota has identified microbial biomarkers related to diseases, which may provide a new direction for the screening, diagnosis and treatment of OP in the future [95]. An association study found that compared with normal BMD patients (N = 60), OP patients (N = 60) had fewer actinomycetes, Egotella, Clostridium group XlVa and Lactobacillus. Compared with osteopenia group (N = 61), the abundance of Escherichia coli/Shigella and Veronella was lower, and there was no statistical difference in diversity indicators between groups [96]; Another study found that the diversity and abundance of dialysis bacteria and fecal bacteria in OP patients (N = 48) were higher than those in normal BMD group (N = 48) [97]; The changes of intestinal microbiota in 44 elderly patients with OP and 64 controls were reported recently: the absolute and relative abundance of Bacteroides, Bacteroides and Eisenberg in OP patients were high. In OP group, the absolute abundance of Clostridium, Fecal coccus, Lactobacillus and Egtehela increased, while that of Menera decreased. Clinical observations supplementation with Bacillus subtilis, Lactobacillus and multiple probiotics has beneficial effects not only on the human gut microbiota but also on bone turnover markers and short-term prevention of lumbar spine bone loss [98], animal studies have shown that probiotic supplementation in mice increases trabecular bone formation postoperatively, and two different clinical trials conducted in Sweden have shown that P, Bone loss is significantly reduced in postmenopausal women using probiotics [99]. The interaction of prebiotics with probiotics to reduce osteoporosis through multiple mechanisms, whether the loss of BMD can be prevented in the long term, also needs to be supported by rigorous scientific investigations [100]. To date, there have been no reports on the effects of FMT on bone health. The characteristics of intestinal flora changes in the above 11 metabolic diseases are shown in Table 1.

Diet is the main factor of microbiota composition, and different time, diet preference and food materials affect our intestinal ecosystem [101]. Host physiology, immune status and metabolic capacity also regulate bacterial colonization and the existence of specific microbial species [102]. Studies have shown that Mediterranean diet has potential health benefits for human body: Mediterranean diet has anti-inflammatory and regulating effects on intestinal flora, and reduces the ratio of chlamydomonas/bacteroides in patients [103]. Ketogenic diet (KD) can increase the genetic diversity of microbiota and the proportion of Bacteroides and Firmicum [104], reduce the HbA1c of diabetic patients, reduce the demand for insulin [105], reduce weight loss, visceral obesity and control appetite [106], reduce LDL, increase HDL and reduce TG to improve lipid status [107]. The dietary fiber provided by the high dietary fiber diet is mainly fermented by Firmicum and other bacteria, which increases the production of SCFA, such as acetate, propionate and butyrate [108]. Butyric acid is an important mediator of intestinal flora and host metabolic health, affects body weight, body composition and glucose homeostasis, and improves obesity and hyperglycemia/hyperinsulinemia induced by high-fat diet [109].

Probiotics are living non pathogenic microorganisms. When given enough (at least 10⁶ live CFU/g), they are beneficial to the host by improving the microbial balance in the intestine and participating in metabolism [102] [110]. The role of probiotics [111], see Figure 2.

By strengthening the epithelial connection and maintaining the mucosal barrier function, it shows the cytoprotective effect on the integrity of intestinal mucosa, enhances the intestinal barrier function, and regulates intestinal peristalsis [112]. Supplementing probiotics can not only increase bone density, but also prevent primary (estrogen deficiency) and secondary osteoporosis [113], reduce cholesterol, prevent cancer, resist mutagenesis and allergy [114]. It can antagonize pathogenic bacteria through space competition and competition for nutrients in the intestinal cavity and wall [115], produce antibacterial agents, organic acids and bacteriocins, stimulate intestinal flora to produce mucin, and prevent the implantation of pathogens, Enhance the immune regulation of intestinal system and inhibit the production of bacterial toxins [116]. Clinical application of probiotics can improve the symptoms of metabolic diseases. 50 subjects with body mass index over 25 kg/m² were randomly divided into probiotics group or placebo group. Each group received unlabeled placebo or probiotic capsules for 12 weeks. Body weight, waist circumference and body composition were measured every 3 weeks. Results: In the placebo group, the percentage of fat, blood glucose and insulin in the intestinal type patients rich in Pleurotus pumilus were significantly increased. The obesity related markers, such as waist circumference, total fat area, visceral fat and the ratio of visceral to subcutaneous fat area, were significantly reduced in the probiotic group. The decrease of obesity related markers in intestinal type patients rich in Plasmobacter spp. was greater than that in intestinal type patients rich in Bacteroides [117]. In patients with type 2 diabetes, probiotics can reduce bacterial translocation and change intestinal microbiota [118]. The effectiveness of probiotics on metabolic diseases needs further observation. Although the safety is good, attention should be paid to the occurrence of adverse reactions. Some people have summarized them into four categories: 1) systemic infection, 2) harmful metabolic activities, 3) excessive immune stimulation, 4) unwanted gene transfer [119]. They should be carefully applied to patients with low immune function.

Prebiotics are undigested carbohydrates in the small intestine, active in the colon, fermented by bacteria in the colon, which affect the production of SCFA, regulate the production of mucin and local inflammatory response of intestinal associated lymphoid tissue, thus stimulating the phagocytosis of macrophages [120]. Compared with placebo, prebiotics supplementation for overweight and obese children can significantly improve satiety (P = 0.04), reduce expected food consumption (P = 0.03), and significantly reduce energy intake of children aged 11 and 12 (P = 0.04). The trend of reducing BMI z score to a greater extent is (−3.4%; P = 0.09), which leads to the reduction of energy intake of older but younger children in buffet breakfast [121]; After the intervention of prebiotics on T2DM for two months, anthropometric variables, blood pressure and blood lipids in the treatment group were significantly improved (P < 0.001). Serum IL-4, IL-12 and IFN in intervention group γ. The concentration also decreased significantly (P < 0.001), and it has some beneficial effects on improving the blood glucose, blood pressure, blood lipid status and immune markers of patients with T2DM [122]; Prebiotic inulin was 10 g/day for 3 months. 75 cases of NAFLD were treated with prebiotic inulin, which improved the fatty liver grade and serum transaminase level [123].

Synbiotics are a combination of prebiotics and probiotics [120]. Bifidobacterium brevis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, 10⁹ CFU/g plus 35 mg oligosaccharide for 8 weeks. 76 Obesity improves serum insulin level and insulin resistance [124]; Bifidobacterium W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus casei W56, Lactobacillus brevis W63, Lactobacillus salivarius W24,Lactococcus lactis W58, Lactococcus lactis W19, plus galactooligosaccharide P11 and fructooligosaccharide P6 1.5 × 10¹⁰CFU plus 8 g, 6 months, T2DM, diabetes improved hip circumference, zonulin and lipoprotein, and did not affect glucose metabolism [125]; Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus casei, with chicory inulin 7 × 10⁹ CFU with chicory inulin 100 mg 4-month 28 NAFLD improves fatty liver Grade and inflammation, antioxidant status [126].

Postbiotics are preparations of abiotic microorganisms and/or their components that are beneficial to the health of the host; postbiotics are not purified microbial metabolites and vaccines, but are not limited to inactivated probiotics; The beneficial effects of epigenetic elements on the target host and the use safety must be confirmed; The five mechanisms of postbiotics: 1) beneficial regulation of microbiome; 2) Enhancing epithelial barrier function; 3) Regulate local and systemic immunity; 4) Regulate systemic metabolism; 5) Sending signals through the nervous system; The target of postbiotics is not limited to the intestinal tract, but must be administered on the host surface, such as oral cavity, intestinal tract, skin, urogenital tract or nasopharynx. Injection does not belong to the scope of postbiotics [127]. Animal experimental study on metabolic diseases: Lactobacillus plantarum L-14 extracellular polysaccharide upregulates TLR2-AMPK pathway in obese mice [128]. Butyric acid upregulates GPR43-NLCR3-TRAF6 pathway in experimental animals with type 2 diabetes [129]. Butyric acid increased ZO-1 expression and decreased endotoxin level in NAFLD mice [130]. Clinical observation: supplementation of hydroxybutyrate methyl ester, leucine, glutamine and arginine to 34 patients with diabetes related sarcopenia can inhibit skeletal muscle catabolism and improve digestive tract function [131]; Results of butyric acid treatment on 80 patients with dysentery with metabolic disorder: it can reduce the pathological damage of colon mucosal barrier and enhance the release of antimicrobial peptides [132].

Minocycline is an antibiotic of the tetracycline family. It can be absorbed quickly in the intestine, easily penetrate the blood brain barrier, and has been clinically applied for decades. It has good safety performance and dual characteristics of antibiotic and anti-inflammatory. Minocycline can rebalance the intestinal microbiota composition of hypertensive rats to that of normal blood pressure animals [133]. In experimental colitis and other intestinal inflammatory diseases, the drug has good efficacy, can induce mucosal healing and reduce intestinal inflammation [134]. Minocycline can prevent the occurrence of diabetic retinopathy in rodent models [135]: an observational study on patients with T2DM showed that in a group of patients withT2DM, it reduced glycosylated hemoglobin, lowered blood pressure, improved vision and symptoms related to neuropathy [136]. An open label study of minocycline on patients with high risk and refractory HTN [137] showed that 16 of 26 patients (62%) responded to minocycline, the daily dynamic mean systolic pressure decreased (135/74 to 124/68 mmHg), the daily dynamic systolic pressure decreased, and minocycline treatment reduced the number of intestinal inflammatory cells. These observations suggest that minocycline may be beneficial to neuroinflammation, intestinal microorganisms and their pathophysiology, intestinal immunity and other mechanisms [137].

FMT is a strategy to transplant the whole intestinal microbiota of healthy donors to diseased recipients [138]. Research shows that FMT can widely affect the intestinal microbiota of recipients, and it is the most effective choice to regulate the intestinal microbiota. Since 2013, FMT has been recommended to treat recurrent Clostridium difficile infection resistant to standard nursing care [139], and is an effective method to treat recurrent Clostridium difficile infection. It has potential therapeutic effect on gastrointestinal diseases and nervous system diseases. FMT is mainly applied to common metabolic diseases (such as MetS, Obesity and T2DM [140], HTN [141]). A double-blind randomized controlled trial of fecal microbiota transplantation (FMT) for treatment of type 2 diabetes mellitus for 24 weeks showed that repeated FMT could improve the level and time of microbiota implantation in obese T2DM patients. The combination of lifestyle intervention and FMT can make more favorable changes in the microbiota of the recipient, and improve the blood lipid level and liver hardness. The impact on blood glucose has not been reported, which needs further research in the future [142]. In the animal experiment of ischemic cerebrovascular disease, gavage of mice with normal microbiota can reduce the infarct volume [143]. Compared with receiving fecal bacteria from old mice, stroke mice receiving fecal bacteria from young mice improved several behavior tests, reduced mortality and infarct area, and reduced proinflammatory cytokines [144]. A study on the treatment of HTN patients with washing intestinal flora transplantation (WMT) showed that WMT had effect of lowering blood pressure on HTN patients, especially those with WMT through the lower digestive tract and those without anti-hypertensive drugs [141].